Please ensure Javascript is enabled for purposes of website accessibility

Fresno City Gets Extension in Herndon 4-Story Apartment Case

4 hours ago

With Major Heat Risk Forecast, This Is a Good Weekend to Stay Indoors in Fresno

6 hours ago

Trump Says Intel Has Agreed to Deal for US to Take 10% Equity Stake

7 hours ago

Epstein Associate Maxwell Says She Never Saw Trump Behave Inappropriately

7 hours ago

Pew: US Immigrant Population Declines for First Time in Nearly 60 Years

9 hours ago

Powell, Citing Jobs Risk, Opens Door to Cuts but Doesn’t Commit

11 hours ago

FBI Agents Search Ex-Trump Adviser Bolton’s Home, Source Says

12 hours ago

Gaza City Officially in Famine, With Hunger Spreading, Says Global Hunger Monitor

12 hours ago

Gavin Newsom’s Redistricting Plan Is on Its Way to Voters. What You Need to Know

1 day ago
Moderna Starting Last Trial of COVID-19 Vaccine, Expects to Make up to 1 Billion Doses a Year
TLBBHMAP3-U010ALB5ANM-348f959abae2-512-300x300-1
By Jim Jakobs, Digital Producer
Published 5 years ago on
July 16, 2020

Share

Moderna is targeting July 27 to begin phase 3 testing of their COVID-19 vaccine. The company is looking for thousands of volunteers to participate.

The Cambridge, Massachusetts-based biotech company is the first to announce an estimated start date for phase 3 trials in the United States.

Newly released data from earlier human trials showed their vaccine candidate appears to be safe and provide some immunity. The most commonly reported systemic adverse events following second vaccination at the 100 microgram dose were fatigue (80%), chills (80%), headache (60%), and myalgia (53%), all of which were moderate in severity. The most common local adverse event at the 100 microgram dose was pain at the injection site (100%), which was also transient and mild or moderate in severity.

(Moderna Facebook)

New data from early trials shows Moderna’s COVID-19 vaccine candidate appears to be safe and provide some immunity.

Guidance for Vaccine Volunteers

Information about the trial, including guidance for vaccine volunteers, was posted on clinicaltrials.gov on Tuesday.

A brief summary posted on the site says, “The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.”

Moderna describes mRNA as like software for the cell; mRNA medicines are sets of instructions. And these instructions direct cells in the body to make proteins to prevent or fight disease.

Below is a video Moderna posted to its Facebook page describing the use of mRNA therapeutics.

https://www.facebook.com/modernatx/videos/725992207466392/

For inclusion in the study, volunteers must meet several criteria including the following:

  • Participants who are at high risk of SARS-CoV-2 infection, defined as adults whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and COVID-19.
  • Understands and agrees to comply with the study procedures and provides written informed consent.
  • Able to comply with study procedures based on the assessment of the Investigator.
  • Female participants of non-childbearing potential may be enrolled in the study.
  • Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:
    • Has a negative pregnancy test at Screening and on the day of the first dose (Day 1).
    • Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1).
    • Has agreed to continue adequate contraception through three months following the second dose on Day 29.
    • Is not breastfeeding.
  • Male participants engaging in activity that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the time of the first dose and through three months after the second dose.
  • Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the three months before enrollment.

Moderna tweeted information and a link about the study Tuesday.

California Study Locations

Several locations throughout California will be utilized and volunteers will be needed for each.

  • Advanced Clinical Research, Rancho Paseo in Banning
  • University of California San Diego in La Jolla
  • eStudySite in La Mesa
  • UCLA Vine Street Clinic CRS  in Los Angeles
  • Paradigm Clinical Research Institute Inc. in Redding
  • Benchmark Research in Sacramento
  • Medical Center For Clinical Research, M3 Wake Research in San Diego

If you are interested, contact Moderna Clinical Trials at (855) 663-6762 or email clinicaltrials@modernatx.com

The randomized, placebo-controlled trial is expected to include approximately 30,000 participants at the 100 microgram dose level in the U.S.

Early Results Encouraging

Moderna’s experimental vaccine against the coronavirus showed encouraging results in early testing.

COVID-19 antibodies were found in all 45 participants, the biotech company announced in a May news release.

Neal Browning of Bothell, Washington, spoke to GV Wire via Zoom shortly after the early testing results were made public.

“I’m the second person to receive the vaccine in a small dose so that means I’ve got the antibodies,” Browning said. “One of the first people to reach out to me was Jennifer Haller, the lady who was the first to receive the vaccine. She was super excited, too. We chatted a little bit on text about that.”

Neal Browning becomes the second volunteer to receive the investigational COVID-19 vaccine in the NIH-supported clinical trial in Seattle. (AP File)

Moderna said the early vaccine data indicated that it provided full protection against viral replication in the lungs in a mouse challenge model.

An interim analysis just published in The New England Journal of Medicine shows mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2.

In a press release, Moderna says, “After two vaccinations, mRNA-1273 elicited robust neutralizing antibody titers. At Day 43, neutralizing activity against SARS-CoV-2 was seen in all evaluated participants.”

Moderna has posted a video of a conference call on Wednesday providing more information to investors.

500 Million Doses a Year

Moderna is working closely with Operation Warp Speed and the NIH, including NIAID’s COVID-19 Prevention Trials Network to conduct the Phase 3 study.

With the Phase 3 dose being finalized at 100 micrograms, the company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the company’s internal U.S. manufacturing site and strategic collaboration with Lonza.

In addition, Moderna recently announced a collaboration with Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent’s biologics facility in Indiana. On July 9, Moderna announced a collaboration with ROVI for large-scale, commercial fill-finish manufacturing of mRNA-1273 intended in principle to supply markets outside of the U.S. starting in early 2021 at ROVI’s facility in Madrid, Spain.

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Fresno Crash Sends Car Into Building After Running Red Light

DON'T MISS

Fresno City Gets Extension in Herndon 4-Story Apartment Case

DON'T MISS

Atwater Prison Inmate Charged for Threatening to Kill Prosecutor’s Family

DON'T MISS

Multiple Passengers Are Killed After Bus Crashes in Western New York

DON'T MISS

Fresno Firefighters Contain Cambridge Avenue Blaze, No Injuries Reported

DON'T MISS

With Major Heat Risk Forecast, This Is a Good Weekend to Stay Indoors in Fresno

DON'T MISS

Trump Says Intel Has Agreed to Deal for US to Take 10% Equity Stake

DON'T MISS

Epstein Associate Maxwell Says She Never Saw Trump Behave Inappropriately

DON'T MISS

Wrongly Deported Migrant Abrego to Be Released Soon, Lawyer Says

DON'T MISS

Remembering Ron McCary, Who Did It All for KMJ

UP NEXT

Texas Senate Debates Redistricting Bill, Is Expected to Pass It Easily

UP NEXT

Trump: DC Mayor Bowser Must Get Act Together or Won’t Be Mayor Anymore

UP NEXT

Wall Street Soars as Powell Hints at Rate Cut in September

UP NEXT

Trump’s Tariffs Could Reduce US Deficit by $4 Trillion, CBO Estimates

UP NEXT

Pew: US Immigrant Population Declines for First Time in Nearly 60 Years

UP NEXT

Canada to Remove Many Retaliatory Tariffs on US Goods, Says Source

UP NEXT

After Joining TikTok, Trump Says He Could Extend Sale Deadline if Needed

UP NEXT

Powell, Citing Jobs Risk, Opens Door to Cuts but Doesn’t Commit

UP NEXT

FBI Agents Search Ex-Trump Adviser Bolton’s Home, Source Says

UP NEXT

Gaza City Officially in Famine, With Hunger Spreading, Says Global Hunger Monitor

Multiple Passengers Are Killed After Bus Crashes in Western New York

5 hours ago

Fresno Firefighters Contain Cambridge Avenue Blaze, No Injuries Reported

5 hours ago

With Major Heat Risk Forecast, This Is a Good Weekend to Stay Indoors in Fresno

6 hours ago

Trump Says Intel Has Agreed to Deal for US to Take 10% Equity Stake

7 hours ago

Epstein Associate Maxwell Says She Never Saw Trump Behave Inappropriately

7 hours ago

Wrongly Deported Migrant Abrego to Be Released Soon, Lawyer Says

7 hours ago

Remembering Ron McCary, Who Did It All for KMJ

7 hours ago

I Was Preyed On for My VA Benefits. California Can Stop It

8 hours ago

Texas Senate Debates Redistricting Bill, Is Expected to Pass It Easily

8 hours ago

Trump: DC Mayor Bowser Must Get Act Together or Won’t Be Mayor Anymore

8 hours ago

Fresno Crash Sends Car Into Building After Running Red Light

A driver ran a red light Friday at the intersection of Herndon and West avenues, clipping another vehicle before crashing into a nearby buil...

4 hours ago

4 hours ago

Fresno Crash Sends Car Into Building After Running Red Light

4 hours ago

Fresno City Gets Extension in Herndon 4-Story Apartment Case

The crest of the United States Department of Justice (DOJ) is seen at their headquarters in Washington, D.C., U.S., May 10, 2021. REUTERS/Andrew Kelly/File photo
5 hours ago

Atwater Prison Inmate Charged for Threatening to Kill Prosecutor’s Family

First responders work at the scene of a bus crash on the New York State Thruway about 30 miles east of Buffalo, N.Y., on Friday afternoon, Aug. 22, 2025. The tour bus traveling from Niagara Falls to New York City crashed on a highway outside Buffalo on Friday, killing multiple passengers, including at least one child, and leaving some people trapped beneath the vehicle, officials said. (Lauren Petracca/The New York Times)
5 hours ago

Multiple Passengers Are Killed After Bus Crashes in Western New York

On Friday, August 22, 2025, Fresno firefighters contained a house fire on East Cambridge Avenue, preventing major damage and reporting no injuries. (Fresno Fire)
5 hours ago

Fresno Firefighters Contain Cambridge Avenue Blaze, No Injuries Reported

Fresno heat hot heatwave High Humidity
6 hours ago

With Major Heat Risk Forecast, This Is a Good Weekend to Stay Indoors in Fresno

A smartphone with a displayed Intel logo is placed on a computer motherboard in this illustration taken March 6, 2023. (Reuters File)
7 hours ago

Trump Says Intel Has Agreed to Deal for US to Take 10% Equity Stake

Ghislaine Maxwell appears via video link during her arraignment hearing in Manhattan Federal Court, in the Manhattan borough of New York City, New York, U.S. July 14, 2020 in this courtroom sketch. (Reuters File)
7 hours ago

Epstein Associate Maxwell Says She Never Saw Trump Behave Inappropriately

Search

Help continue the work that gets you the news that matters most.

Send this to a friend